This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Siplizumab
- DrugBank Accession Number
- DB06371
- Background
Not Available
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Structure
- Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Siplizumab
- External IDs
- MEDI-507
Pharmacology
- Indication
Investigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified).
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Siplizumab has been shown to cause depletion of T-cells. It is therefore considered to be an immunomodulator in clinical settings where the depletion of T-cells may have clinical benefits, such as certain autoimmune diseases and T-cell cancers. In addition, preclinical studies have also suggested that siplizumab, by binding to the CD2 receptor, may selectively produce cell death and reduce cancerous cells.
Target Actions Organism UT-cell surface antigen CD2 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Siplizumab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Siplizumab. Aducanumab The risk or severity of adverse effects can be increased when Siplizumab is combined with Aducanumab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Siplizumab. Alirocumab The risk or severity of adverse effects can be increased when Siplizumab is combined with Alirocumab. Amivantamab The risk or severity of adverse effects can be increased when Siplizumab is combined with Amivantamab. Anifrolumab The risk or severity of adverse effects can be increased when Siplizumab is combined with Anifrolumab. Ansuvimab The risk or severity of adverse effects can be increased when Siplizumab is combined with Ansuvimab. Anthrax immune globulin human The risk or severity of adverse effects can be increased when Siplizumab is combined with Anthrax immune globulin human. Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Siplizumab is combined with Antilymphocyte immunoglobulin (horse). 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- KUW1QG1ZM3
- CAS number
- 288392-69-8
References
- General References
- Not Available
- External Links
- Wikipedia
- Siplizumab
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Kidney Transplantation / Renal Failure, Chronic Renal Failure 1 2 Completed Treatment Psoriasis (PsO) 1 2 Completed Treatment Psoriasis Vulgaris (Plaque Psoriasis) 1 2 Not Yet Recruiting Prevention Kidney Transplantation 1 2 Terminated Treatment Leukemias / Lymphoma / Multiple Myeloma (MM) / Myelodysplastic Syndrome 1 1 Completed Treatment Cancer / Graft-versus-host Disease (GVHD) 1 1 Completed Treatment Graft-versus-host Disease (GVHD) 2 1 Completed Treatment Hepatosplenic Gamma/ Delta T-cell Lymphoma / NK/T-cell Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Subcutaneous Panniculitis-Like T-Cell Lymphoma 1 1 Completed Treatment Kidney Diseases 1 1 Recruiting Treatment Kidney Failure 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Receptor binding
- Specific Function
- CD2 interacts with lymphocyte function-associated antigen (LFA-3) and CD48/BCM1 to mediate adhesion between T-cells and other cell types. CD2 is implicated in the triggering of T-cells, the cytopla...
- Gene Name
- CD2
- Uniprot ID
- P06729
- Uniprot Name
- T-cell surface antigen CD2
- Molecular Weight
- 39447.96 Da
Drug created at March 19, 2008 16:27 / Updated at February 21, 2021 18:52